HYUNDAI BIOLAND Co.,Ltd.
KKRX:0522604,325.00
KRW
-80.00
(-1.82%)
ISIN
KR7052260007
Return %
Stock
S&P 500
1Y
-4.74
14.39
3Y
-6.89
81.42
5Y
-54.95
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hui-Joon Lee
- Full Time Employees
- 342
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- Cheongju-si South Korea
- IPO Date
- May 17, 2001
- Website
- hyundaibioland.co.kr
- Similar Companies
- Business
- HYUNDAI BIOLAND Co.,Ltd. is a South Korea-based biotechnology company engaged in the development, manufacturing, and distribution of natural active ingredients and biomaterials for the cosmetics, health functional food, and biomedical industries. Founded in 1995 and headquartered in Cheongju-si, Chungcheongbuk-do, South Korea, the company operates as the core healthcare and life sciences affiliate of the Hyundai Department Store Group. The company operates through three primary business divisions: Cosmetic Ingredients, Health Supplements (Nutraceuticals), and Biomedical Materials. In the Cosmetic Ingredients division, HYUNDAI BIOLAND manufactures a portfolio of over 500 botanical extracts, bioactive compounds, and functional raw materials utilizing natural extraction, separation, fermentation, and bioconversion technologies; its product offerings include sodium hyaluronate (Bio-Sodium Hyaluronate); oil-soluble hyaluronic acid formulations (HYALWAX); skin-soothing botanical extracts (including Portulaca Oleracea extract); whitening and brightening agents (including arbutin); and barrier-enhancing plant-derived ceramides (including Citron Ceramide). In the Health Supplements division, the company manufactures functional health food ingredients aimed at immunity enhancement, joint health, body fat management, and digestive wellness; it also provides commercial development and finished product distribution services. In the Biomedical Materials division, the company develops regenerative medical devices and collagen-based matrices for dental, orthopedic, and dermatological applications; primary products include resorbable collagen membranes (OssGuide and T-Gen) utilized in guided bone regeneration (GBR) and periodontal tissue repair; collagen wound healing dressings; and medical-grade sodium hyaluronate. HYUNDAI BIOLAND serves multinational cosmetics manufacturers, pharmaceutical enterprises, dental clinics, and dietary supplement providers across more than 35 countries. The company operates multiple research and manufacturing complexes in South Korea, including facilities in Osong, Ochang, Cheonan, and Ansan, as well as an international manufacturing facility in Haimen, China. In recent strategic developments, HYUNDAI BIOLAND has significantly expanded its consumer healthcare business through a strategic alliance with Nestlé Health Science, securing exclusive South Korean import and distribution rights for global nutritional supplement brands, including Solgar, Vital Proteins, Nuun, and Egmont Manuka Honey, while opening dedicated retail health stores incorporating artificial intelligence-driven diagnostic tools. Furthermore, the company continues to expand its global bio-ingredients commercialization network through distribution agreements with international partners such as DKSH, alongside the continuous rollout of next-generation bio-fermentation and oil-soluble active cosmetic ingredients.